Activation of the signal transducer and activator of transcription 3 pathway Up-regulates estrogen receptor-β expression in lung adenocarcinoma cells

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Estrogens contribute to the pathogenesis of female lung cancer and function mainly through estrogen receptor-β (ERβ). However, the way in which ERβ expression is regulated in lung cancer cells remains to be explored. We have found that signal transducer and activator of transcription 3 (Stat3) activation up-regulates ERβ expression in PC14PE6/AS2 lung cancer cells in a preliminary Affymetrix oligonucleotide array study, and we sought to confirm the findings. In this study, we show that IL-6 induced ERβ mRNAand protein expression in lung cancer cells. The induction of ERβin response to IL-6 was abolished by Janus kinase 2 inhibitor-AG490, dominant-negative mutant of Stat3, and Stat3-targeting short interfering RNA. The luciferase reporter assay and chromatin immunoprecipitation assay confirmed that IL-6-activated Stat3 binds to the ER promoter. Besides the Janus kinase 2/Stat3 pathway, the MEK/Erk pathway contributes to ERβ up-regulation inducedby IL-6; however, the phosphoinositide -3'kinase/Akt pathway does not. We also found that epidermal growth factor (EGF) stimulation or L858R mutation in EGF receptor (EGFR) induced Stat3 activation as well as ERβ expression in lung cancer cells. Inhibiting Stat3 activity by pharmacological or genetic approaches reduced EGF- and L858R mutant EGFR-induced ERβ expression, indicating that Stat3 activation is required for EGFR signaling-mediated ERβ up-regulation. Silencing ERβ decreased cell proliferation in lung cancer cells that overexpress L858R mutant EGFR. In conclusion, we have identified that Stat3 activation is essential for ERβ induction by IL-6, EGF, and the presence of EGFR mutation. The findings shed lightonnewtherapeutic targets for female lung cancer, especially for those with EGFR mutations.

Original languageEnglish
Pages (from-to)1145-1158
Number of pages14
JournalMolecular Endocrinology
Volume25
Issue number7
DOIs
Publication statusPublished - 2011 Jul 1

Fingerprint

STAT3 Transcription Factor
Estrogen Receptors
Up-Regulation
Lung Neoplasms
Epidermal Growth Factor Receptor
Interleukin-6
Transcriptional Activation
Epidermal Growth Factor
Janus Kinase 2
Mutation
Adenocarcinoma of lung
1-Phosphatidylinositol 4-Kinase
Chromatin Immunoprecipitation
Mitogen-Activated Protein Kinase Kinases
Oligonucleotide Array Sequence Analysis
Luciferases
Small Interfering RNA
Estrogens
Cell Proliferation
Pharmacology

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Endocrinology

Cite this

@article{2d3cd336ef7c45f2bea8b1e34d0729a9,
title = "Activation of the signal transducer and activator of transcription 3 pathway Up-regulates estrogen receptor-β expression in lung adenocarcinoma cells",
abstract = "Estrogens contribute to the pathogenesis of female lung cancer and function mainly through estrogen receptor-β (ERβ). However, the way in which ERβ expression is regulated in lung cancer cells remains to be explored. We have found that signal transducer and activator of transcription 3 (Stat3) activation up-regulates ERβ expression in PC14PE6/AS2 lung cancer cells in a preliminary Affymetrix oligonucleotide array study, and we sought to confirm the findings. In this study, we show that IL-6 induced ERβ mRNAand protein expression in lung cancer cells. The induction of ERβin response to IL-6 was abolished by Janus kinase 2 inhibitor-AG490, dominant-negative mutant of Stat3, and Stat3-targeting short interfering RNA. The luciferase reporter assay and chromatin immunoprecipitation assay confirmed that IL-6-activated Stat3 binds to the ER promoter. Besides the Janus kinase 2/Stat3 pathway, the MEK/Erk pathway contributes to ERβ up-regulation inducedby IL-6; however, the phosphoinositide -3'kinase/Akt pathway does not. We also found that epidermal growth factor (EGF) stimulation or L858R mutation in EGF receptor (EGFR) induced Stat3 activation as well as ERβ expression in lung cancer cells. Inhibiting Stat3 activity by pharmacological or genetic approaches reduced EGF- and L858R mutant EGFR-induced ERβ expression, indicating that Stat3 activation is required for EGFR signaling-mediated ERβ up-regulation. Silencing ERβ decreased cell proliferation in lung cancer cells that overexpress L858R mutant EGFR. In conclusion, we have identified that Stat3 activation is essential for ERβ induction by IL-6, EGF, and the presence of EGFR mutation. The findings shed lightonnewtherapeutic targets for female lung cancer, especially for those with EGFR mutations.",
author = "Wang, {Hao Chen} and Yeh, {Hsuan Heng} and Huang, {Wei Lun} and Lin, {Chien Chung} and Su, {Wen Pin} and Chen, {Helen H.W.} and Lai, {Wu Wei} and Su, {Wu Chou}",
year = "2011",
month = "7",
day = "1",
doi = "10.1210/me.2010-0495",
language = "English",
volume = "25",
pages = "1145--1158",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Activation of the signal transducer and activator of transcription 3 pathway Up-regulates estrogen receptor-β expression in lung adenocarcinoma cells

AU - Wang, Hao Chen

AU - Yeh, Hsuan Heng

AU - Huang, Wei Lun

AU - Lin, Chien Chung

AU - Su, Wen Pin

AU - Chen, Helen H.W.

AU - Lai, Wu Wei

AU - Su, Wu Chou

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Estrogens contribute to the pathogenesis of female lung cancer and function mainly through estrogen receptor-β (ERβ). However, the way in which ERβ expression is regulated in lung cancer cells remains to be explored. We have found that signal transducer and activator of transcription 3 (Stat3) activation up-regulates ERβ expression in PC14PE6/AS2 lung cancer cells in a preliminary Affymetrix oligonucleotide array study, and we sought to confirm the findings. In this study, we show that IL-6 induced ERβ mRNAand protein expression in lung cancer cells. The induction of ERβin response to IL-6 was abolished by Janus kinase 2 inhibitor-AG490, dominant-negative mutant of Stat3, and Stat3-targeting short interfering RNA. The luciferase reporter assay and chromatin immunoprecipitation assay confirmed that IL-6-activated Stat3 binds to the ER promoter. Besides the Janus kinase 2/Stat3 pathway, the MEK/Erk pathway contributes to ERβ up-regulation inducedby IL-6; however, the phosphoinositide -3'kinase/Akt pathway does not. We also found that epidermal growth factor (EGF) stimulation or L858R mutation in EGF receptor (EGFR) induced Stat3 activation as well as ERβ expression in lung cancer cells. Inhibiting Stat3 activity by pharmacological or genetic approaches reduced EGF- and L858R mutant EGFR-induced ERβ expression, indicating that Stat3 activation is required for EGFR signaling-mediated ERβ up-regulation. Silencing ERβ decreased cell proliferation in lung cancer cells that overexpress L858R mutant EGFR. In conclusion, we have identified that Stat3 activation is essential for ERβ induction by IL-6, EGF, and the presence of EGFR mutation. The findings shed lightonnewtherapeutic targets for female lung cancer, especially for those with EGFR mutations.

AB - Estrogens contribute to the pathogenesis of female lung cancer and function mainly through estrogen receptor-β (ERβ). However, the way in which ERβ expression is regulated in lung cancer cells remains to be explored. We have found that signal transducer and activator of transcription 3 (Stat3) activation up-regulates ERβ expression in PC14PE6/AS2 lung cancer cells in a preliminary Affymetrix oligonucleotide array study, and we sought to confirm the findings. In this study, we show that IL-6 induced ERβ mRNAand protein expression in lung cancer cells. The induction of ERβin response to IL-6 was abolished by Janus kinase 2 inhibitor-AG490, dominant-negative mutant of Stat3, and Stat3-targeting short interfering RNA. The luciferase reporter assay and chromatin immunoprecipitation assay confirmed that IL-6-activated Stat3 binds to the ER promoter. Besides the Janus kinase 2/Stat3 pathway, the MEK/Erk pathway contributes to ERβ up-regulation inducedby IL-6; however, the phosphoinositide -3'kinase/Akt pathway does not. We also found that epidermal growth factor (EGF) stimulation or L858R mutation in EGF receptor (EGFR) induced Stat3 activation as well as ERβ expression in lung cancer cells. Inhibiting Stat3 activity by pharmacological or genetic approaches reduced EGF- and L858R mutant EGFR-induced ERβ expression, indicating that Stat3 activation is required for EGFR signaling-mediated ERβ up-regulation. Silencing ERβ decreased cell proliferation in lung cancer cells that overexpress L858R mutant EGFR. In conclusion, we have identified that Stat3 activation is essential for ERβ induction by IL-6, EGF, and the presence of EGFR mutation. The findings shed lightonnewtherapeutic targets for female lung cancer, especially for those with EGFR mutations.

UR - http://www.scopus.com/inward/record.url?scp=79959815001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959815001&partnerID=8YFLogxK

U2 - 10.1210/me.2010-0495

DO - 10.1210/me.2010-0495

M3 - Article

C2 - 21546410

AN - SCOPUS:79959815001

VL - 25

SP - 1145

EP - 1158

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 7

ER -